Paloma Partners’s Corcept Therapeutics CORT Stock Holding History

Paloma Partners’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-13,054	Closed	-$158K	–	1380
2019 Q4	$158K	Sell	13,054 -11,246	-46%	-$157K	﹤0.01%	2010
2019 Q3	$343K	Buy	+24,300	New	+$299K	0.01%	1435
2019 Q1	–	Sell	-12,907	Closed	-$173K	–	1719
2018 Q4	$173K	Buy	+12,907	New	+$171K	0.01%	1075
2018 Q2	–	Sell	-35,605	Closed	-$586K	–	1701
2018 Q1	$586K	Buy	+35,605	New	+$660K	0.01%	1282
2017 Q4	–	Sell	-62,439	Closed	-$1.21M	–	1936
2017 Q3	$1.21M	Sell	62,439 -4,784	-7%	-$71.3K	0.02%	1061
2017 Q2	$793K	Buy	+67,223	New	+$731K	0.01%	1313
2016 Q2	–	Sell	-23,183	Closed	-$109K	–	2169
2016 Q1	$109K	Buy	+23,183	New	+$90.3K	﹤0.01%	1757
2015 Q4	–	Sell	-15,225	Closed	-$58K	–	1734
2015 Q3	$58K	Buy	+15,225	New	+$77.3K	﹤0.01%	1542

Other funds holding CORT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return

Paloma Partners's CORT Position: Q1 2020 in Review

Paloma Partners sold out of Corcept Therapeutics (CORT) in Q1 2020, closing a stake of 13,054 shares — an estimated $158K sold.

Paloma Partners first reported a position in CORT in Q3 2015 and held it in 8 quarters. The position peaked at $1.21M in Q3 2017. 204 funds tracked by Wall St. Rank hold CORT as of Q1 2020.

Paloma Partners reported no remaining Corcept Therapeutics position as of Q1 2020 after selling out during the quarter.
Paloma Partners sold 13,054 Corcept Therapeutics shares in Q1 2020, an estimated $158K.
Paloma Partners first reported a position in Corcept Therapeutics in Q3 2015 and held it in 8 quarters.
Paloma Partners's Corcept Therapeutics position peaked at $1.21M in Q3 2017.
204 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2020.

Based on Paloma Partners's 13F filing for Q1 2020, filed 15 May 2020.